Open Access<p>An Oncolytic Vaccinia Virus Armed with GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy</p>
Author(s) -
Lili Deng,
Xue Yang,
Jianling Fan,
Yuedi Ding,
Ying Peng,
Duanfu Xu,
Biao Huang,
Zhigang Hu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s249816
Subject(s) - oncolytic virus , vaccinia , cancer research , immunotherapy , virus , cytotoxicity , cytotoxic t cell , in vivo , genetic enhancement , cancer cell , cancer , biology , virology , immunology , medicine , in vitro , immune system , gene , genetics , biochemistry , microbiology and biotechnology , recombinant dna
Targeted oncolytic vaccinia virus is an attractive candidate for cancer therapy due to its replication causing lysis of infected tumor cells as well as a delivery vector to overexpress therapeutic transgenes. This study constructed a novel oncolytic vaccinia virus carrying granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-24 (IL-24) double genes to improve efficacy for cancer therapy.